<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088252</url>
  </required_header>
  <id_info>
    <org_study_id>XUAN20211004</org_study_id>
    <nct_id>NCT05088252</nct_id>
  </id_info>
  <brief_title>Desflurane and Anesthesia Recovery Period in Endonasal Endoscopic Pituitary Adenoma Resection</brief_title>
  <official_title>Effects of Desflurane on the Quality of Anesthesia Recovery Period in Patients Undergoing Endonasal Endoscopic Pituitary Adenoma Resection#a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasal packing is required after endoscopic pituitary adenoma resection. The patient can only&#xD;
      breathe through the mouth. The blood and secretion in the nasal cavity may be inhaled into&#xD;
      the trachea after the operation. GH-secreting pituitary adenoma causes pharyngeal soft tissue&#xD;
      and tongue hypertrophy. These conditions increase the risk of respiratory obstruction and&#xD;
      hypoxemia during anesthesia recovery. Propofol total intravenous anesthesia has a rapid&#xD;
      effect and a low incidence of nausea and vomiting. Patients anesthetized with desflurane&#xD;
      recover quickly is conducive to early recovery of respiratory function and orientation. This&#xD;
      study intends to compare the effects of desflurane and propofol on the quality of anesthesia&#xD;
      recovery period in patients undergoing endonasal endoscopic pituitary adenoma resection and&#xD;
      to provide clinical evidence for the use of desflurane in neurosurgical anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time required of the Aldrete score reached 9 points after drug withdrawal.</measure>
    <time_frame>immediately after the surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Pituitary Neoplasms</condition>
  <arm_group>
    <arm_group_label>Desflurane Inhalational Anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol Total Intravenous Anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <description>After induction, anesthesia will be maintained with 0.8-1.3 MAC desflurane and 0.05-0.2 μg/kg/min remifentanil.</description>
    <arm_group_label>Desflurane Inhalational Anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>After induction, anesthesia will be maintained with 6-8mg/kg/h propofol and 0.05- 0.2 μg/kg/min remifentanil.</description>
    <arm_group_label>Propofol Total Intravenous Anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-65 years;&#xD;
&#xD;
          -  Elective endoscopic transsphenoidal resection of pituitary adenomas;&#xD;
&#xD;
          -  ASA status I-III;&#xD;
&#xD;
          -  Informed consent signed by patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complicated with cerebrovascular disease;&#xD;
&#xD;
          -  Complicated with lung disease, the SpO2 is less than 95% without oxygen inhalation;&#xD;
&#xD;
          -  It is expected to retain endotracheal intubation after operation;&#xD;
&#xD;
          -  The disturbance of consciousness can not cooperate with the evaluation before&#xD;
             operation;&#xD;
&#xD;
          -  Complicated with hypothyroidism;&#xD;
&#xD;
          -  The previous history of neck surgery, burns, radiotherapy;&#xD;
&#xD;
          -  Invasive pituitary adenomas with Knosp grade 4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Ruquan Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Desflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

